Does Molecular Profiling of <i>KRAS</i>-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
Background: Several studies suggest that patients with <i>KRAS</i>-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, <i>KRAS</i> 12c data suggest specific treatment for improving ORR and OS. There is a clear ne...
Main Authors: | Nagla Abdel Karim, Asad Ullah, Peterson Pathrose, Hassana Fathallah, Ashley Perry, John C. Morris, Jiang Wang, Sandra L. Starnes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/7/379 |
Similar Items
-
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
by: Alissa J. Cooper, MD, et al.
Published: (2022-09-01) -
Targeting <i>KRAS</i> Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
by: Iris Z. Uras, et al.
Published: (2020-06-01) -
<i>KRAS</i>-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
by: Serena Ceddia, et al.
Published: (2022-08-01) -
The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
by: Srikar Sama, et al.
Published: (2022-06-01) -
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01)